An immune-related lncRNA model for predicting prognosis, immune landscape and chemotherapeutic response in bladder cancer

• Published in: Scientific reports 2022-02, Vol.12 (1), p.3225-3225, Article 3225
• Main Authors: Hou, Jian, Liang, Songwu, Xie, Zhimin, Qu, Genyi, Xu, Yong, Yang, Guang, Tang, Cheng
• Format: Article
• Language: English
• Subjects: 631/1647/48; 692/4025/1334; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Bladder cancer; Cancer; Cell survival; Cisplatin; Genomes; Humanities and Social Sciences; Humans; Immune checkpoint; Infiltration; Medical prognosis; Methotrexate; multidisciplinary; Non-coding RNA; Prognosis; Risk groups; RNA, Long Noncoding - genetics; RNA, Long Noncoding - metabolism; Science; Science (multidisciplinary); Survival; Transcriptome; Transcriptomes; Urinary Bladder Neoplasms - drug therapy; Urinary Bladder Neoplasms - genetics
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-07334-w

Long noncoding RNAs (lncRNAs) participate in cancer immunity. We characterized the clinical significance of an immune-related lncRNA model and evaluated its association with immune infiltrations and chemosensitivity in bladder cancer. Transcriptome data of bladder cancer specimens were employed from The Cancer Genome Atlas. Dysregulated immune-related lncRNAs were screened via Pearson correlation and differential expression analyses, followed by recognition of lncRNA pairs. Then, a LASSO regression model was constructed, and receiver operator characteristic curves of one-, three- and five-year survival were established. Akaike information criterion (AIC) value of one-year survival was determined as the cutoff of high- and low-risk subgroups. The differences in survival, clinical features, immune cell infiltrations and chemosensitivity were compared between subgroups. Totally, 90 immune-related lncRNA pairs were identified, 15 of which were screened for constructing the prognostic model. The area under the curves of one-, three- and five-year survival were 0.806, 0.825 and 0.828, confirming the favorable predictive performance of this model. According to the AIC value, we clustered patients into high- and low-risk subgroups. High-risk score indicated unfavorable outcomes. The risk model was related to survival status, age, stage and TNM. Compared with conventional clinicopathological characteristics, the risk model displayed higher predictive efficacy and served as an independent predictor. Also, it could well characterize immune cell infiltration landscape and predict immune checkpoint expression and sensitivity to cisplatin and methotrexate. Collectively, the model conducted by paring immune-related lncRNAs regardless of expressions exhibits a favorable efficacy in predicting prognosis, immune landscape and chemotherapeutic response in bladder cancer.